Prostate Cancer - Episode 13
During the conclusion of this panel discussion, the panelists provide their final insights about managed care’s role in castration-resistant prostate cancer (CRPC).
E. David Crawford, MD, explains that as agents continue to develop for the treatment of CRPC, there is a need to better evaluate their roles. He explains that managed care needs to assess which factors are most important to patients and third-party payers.
Michael Kolodziej, MD, explains that although CRPC has entered an exciting era, there are many outstanding challenges that need to be addressed.
Jeffrey D. Dunn, PharmD, MBA, believes that managed care needs to focus on cost trends, address payment reform, invest in information technology, and improve coordination between stakeholders.
David Quinn, MD, suggests that achieving the primary goal of improving care for patients with CRPC begins with a commitment by managed care. He explains that managed care needs to determine which treatment options are the most cost-effective.